Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial

Chandrasekaran, Padmapriyadarsini and Vikas S, Oswal and Chetankumar D, Jain and Mariappan, Muthuvijayalakshmi and Singla, Neeta and Kumar, Santhosh and Daniel, Bella Devaleenal and Jigna D, Dave and Vadgama, Parul and Ramraj, Balaji and Kant, Surya and Anuj K, Bhatnagar and Shanmugam, Sivakumar and Dhamodharan, Paul and Jeyadeepa, Bharathi and Manasi, Palav and Neha V, Shah and Santhanakrishnan, Ramesh Kumar and Ravindra K, Dewan and Nadim, Shekh and Prabhakaran, Rathinam and Arvind B, Sisara and Shubhangi, Dhakulkar Mankar and Jyoti, Bajpai and Upasana, Mittal and Sandeep, Chauhan and Ravinder, Kumar and Mallik, Parmar and Sanjay K, Mattoo and Jyoti, Jaju (2024) Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial, 79(6) (137585). pp. 1-11.

Text 202430.pdf - Published Version Download (898kB)

Abstract

Treatment of drug-resistant tuberculosis with bedaquiline-pretomanid-linezolid regimen has demonstrated good treatment efficacy. Given linezolid’s toxicity profile, prudence suggests reconsidering its dose and duration. We determined the effectiveness and safety of structured dose reduction of linezolid with bedaquiline and pretomanid in adults with pre–extensively drug-resistant (pre-XDR) or treatment-intolerant/nonresponsive multidrug-resistant (MDRTI/NR) pulmonary tuberculosis.

Affiliation:	ICMR-National Institute for Research in Tubercuosis
Item Type:	Article
URI:	http://eprints.nirt.res.in/id/eprint/2065

Actions (login required)

View Item